Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Antonio A. Sánchez-Ruiz"'
Autor:
Miguel A. Alonso García, Francisca Berrocal Berrocal, Daniel Alonso Hernán, María de los Ángeles Gómez Flechoso, Antonio A. Sánchez Ruiz-Granados, Marco Castrillón López
Publikováno v:
INTED2023 Proceedings.
Autor:
Antonio Carlos Sánchez Ruiz, Laura Lee, Linsey Gold, Rakesh Patel, Paul L. Baron, Peter D. Beitsch, Pat Whitworth, Richard J. C. Brown
Publikováno v:
Cancer Research. 80:P2-16
Background: Molecular genomic profiles are increasingly used to guide treatment of refractory cancers and are on the forefront of personalized medicine for select patients. The neoadjuvant chemotherapy (NAC) setting provides a meaningful opportunity
Publikováno v:
Revista espanola de medicina nuclear e imagen molecular. 41(1)
Publikováno v:
Revista Española de Medicina Nuclear e Imagen Molecular. 41:67-68
Autor:
Ed D. Esplin, Linda Ann Smith, Michael Kinney, Patricia Clark, Eric J. Brown, Samuel Lyons, Sadia Kahn, Lisa D. Curcio, P Baron, Linsey Gold, Gia Compagnoni, Dennis R. Holmes, Peter D. Beitsch, Antonio Carlos Sánchez Ruiz, Pat Whitworth, Rakesh R. Patel, Mary Kay Hardwick, Ian Grady, Robert L. Nussbaum, Lee Riley, Cynara Coomer, Shan Yang, Barry Rosen, Heather MacDonald, Karen Barbosa, Rache M. Simmons, Kevin S. Hughes
Publikováno v:
Journal of Clinical Oncology
Purpose An estimated 10% of breast and ovarian cancers result from hereditary causes. Current testing guidelines for germ line susceptibility genes in patients with breast carcinoma were developed to identify carriers of BRCA1/ 2 variants and have ev
Autor:
Peter D. Beitsch, S Lyons, Linsey Gold, Barry P. Rosen, Rakesh Patel, Dennis R. Holmes, Shan Yang, Antonio Carlos Sánchez Ruiz, Rache M. Simmons, Michael Kinney, Heather MacDonald, Patricia Clark, Karen Barbosa, Linda Ann Smith, Cynara Coomer, S Kahn, P Baron, Edward D. Esplin, Eric J. Brown, Lisa D. Curcio, Gia Compagnoni, P Whitworth, Ian Grady, Lee B. Riley
Publikováno v:
Cancer Research. 79:P5-09
Background: Pathogenic genetic variants are estimated to occur in 10-15% of all breast cancer patients, with BRCA 1/2 accounting for 40-50% of pathogenic/likely pathogenic (P/LP) variants. However, it is estimated that Methods: An IRB-approved multic
Autor:
Dennis R. Holmes, Antonio Carlos Sánchez Ruiz, Eric J. Brown, Rache M. Simmons, Shan Yang, Linda Ann Smith, Cynara Coomer, Lisa D. Curcio, Heather MacDonald, Barry P. Rosen, Karen Barbosa, Peter D. Beitsch, Gia Compagnoni, P Whitworth, Ian Grady, Edward D. Esplin, Lee B. Riley, Linsey Gold, S Kahn, S Lyons, Rakesh Patel, Scott T. Michalski, Michael Kinney, Patricia Clark, P Baron
Publikováno v:
Cancer Research. 79:P5-09
Background: The testing of hereditary breast and ovarian cancer (HBOC) patients for BRCA1/2 only was established years ago to identify patients with clinically actionable variants and limit the economic burden. However, the cost of genetic testing ha
Publikováno v:
E-Prints Complutense. Archivo Institucional de la UCM
instname
E-Prints Complutense: Archivo Institucional de la UCM
Universidad Complutense de Madrid
instname
E-Prints Complutense: Archivo Institucional de la UCM
Universidad Complutense de Madrid
Scientific publication and its Peer Review system strongly rely on a few major industry players controlling most journals (e.g. Elsevier), databases (e.g. Scopus) and metrics (e.g. JCR Impact Factor), while keeping most articles behind paywalls. Crit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c91ed1c3296d76e045c7e05a9d04cb
https://eprints.ucm.es/id/eprint/70516/7/1-s2.0-S0306457321002089-main.pdf
https://eprints.ucm.es/id/eprint/70516/7/1-s2.0-S0306457321002089-main.pdf
Publikováno v:
Case-Based Reasoning Research and Development ISBN: 9783030583415
ICCBR
ICCBR
The creation of believable characters is one of the most challenging problems in the interactive entertainment industry. Although there are different tools available for designers and programmers to define the behavior of non-player characters, it re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d29631751387f922b85babd0ee411677
https://doi.org/10.1007/978-3-030-58342-2_17
https://doi.org/10.1007/978-3-030-58342-2_17
Autor:
Eva Tejerina González, Marta Colmena, Constanza Maximiano, Maria Torrente, Mariano Provencio, Lourdes Gutiérrez, Atocha Romero, Miguel Barquín, Estela Sánchez-Herrero, Clara Pérez-Barrios, Manuel García-Espantaleón, Antonio Carlos Sánchez Ruiz, María Soriano
Publikováno v:
Pathology - Research and Practice. 215:392-394
Genetic screening for BRCA mutations should be offered to all women diagnosed with epithelial ovarian, fallopian tube, and/or peritoneal cancers given the implications for treatment options and cancer risk assessments. Yet, while germline breast canc